

Assoc. Prof. HANDE CANPINAR

Personal Information

Email: hcanpina@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/hcanpina>

Address: Hacettepe Üniversitesi Kanser Enstitüsü Temel Onkoloji Anabilim Dalı 06100 Sıhhiye/Ankara

International Researcher IDs

ORCID: 0000-0002-8973-6289

Yoksis Researcher ID: 60751

Education Information

Doctorate, Hacettepe University, Sağlık Bilimleri Enstitüsü, Temel Onkoloji Anabilim Dalı, Turkey 1998 - 2003

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences

Academic Titles / Tasks

Lecturer PhD, Hacettepe University, Kanser Enstitüsü, Temel Onkoloji Anabilim Dalı, 1989 - Continues

Courses

TİM 601 Temel immünoloji I, Postgraduate, 2017 - 2018

KBİ 601 TEMEL İMMÜNOLOJİ I, Postgraduate, 2017 - 2018, 2016 - 2017

KBİ-721 TEMEL İMMÜNOLOJİ I, Doctorate, 2017 - 2018, 2016 - 2017

Advising Theses

CANPINAR H., Expression of toll like receptors in lung cancer and investigating their effect on apoptosis, Postgraduate, H.AINESAZ(Student), 2014

Published journal articles indexed by SCI, SSCI, and AHCI

- Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach**
Kartal B., Denizler-Ebiri F. N., Güven M., Taşpınar F., CANPINAR H., Çetin S., Karaduman T., Küçüktürk S., Castresana J., Taşpınar M.
Medical Oncology, vol.41, no.5, 2024 (SCI-Expanded)
- Pitavastatin induces caspase-mediated apoptotic death through oxidative stress and DNA damage in combined with cisplatin in human cervical cancer cell line**

Haciseyitoğlu A. Ö., DOĞAN T., Dilsiz S., CANPINAR H., EKEN A., Bucurgat Ü. Ü.

Journal of Applied Toxicology, vol.44, no.4, pp.623-640, 2024 (SCI-Expanded)

- III. **Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer**
Beduk Esen C., Gedik M., CANPINAR H., YEDEKÇİ F. Y., YILDIZ F. B., GÜNAYDIN G., GÜLTEKİN M.
Clinical Oncology, vol.35, no.11, pp.744-755, 2023 (SCI-Expanded)
- IV. **A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation**
Pinar S. G., CANPINAR H., TAN Ç., Celebi N.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.171, 2022 (SCI-Expanded)
- V. **Ritonavir nanosuspensions prepared by microfluidization with enhanced solubility and desirable immunological properties**
Karakucuk A., CANPINAR H., Celebi N.
Pharmaceutical Development and Technology, vol.27, no.10, pp.1027-1037, 2022 (SCI-Expanded)
- VI. **Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation**
Kocyigit D., Gurses K. M., Yalcin M. U., CANPINAR H., CANPOLAT U., EVRANOS B., YORGUN H., ÖZER N., GUC D., AYTEMİR K.
JOURNAL OF CLINICAL LABORATORY ANALYSIS, vol.31, no.6, 2017 (SCI-Expanded)
- VII. **Monocyte Toll-Like Receptor Expression in Patients With Atrial Fibrillation**
Gurses K. M., KOÇYİĞİT D., Yalcin M. U., CANPINAR H., YORGUN H., ŞAHİNER M. L., Kaya E. B., OTO M. A., ÖZER N., GÜÇ D., et al.
AMERICAN JOURNAL OF CARDIOLOGY, vol.117, no.9, pp.1463-1467, 2016 (SCI-Expanded)
- VIII. **Enhanced Platelet Toll-like Receptor 2 and 4 Expression in Acute Coronary Syndrome and Stable Angina Pectoris**
Gurses K. M., KOÇYİĞİT D., Yalcin M. U., CANPINAR H., OTO M. A., ÖZER N., Tokgozoglu L., GÜÇ D., AYTEMİR K.
AMERICAN JOURNAL OF CARDIOLOGY, vol.116, no.11, pp.1666-1671, 2015 (SCI-Expanded)
- IX. **Effects of Persistent Atrial Fibrillation on Serum Galectin-3 Levels**
GÜRSES K. M., YALÇIN M. U., KOÇYİĞİT D., CANPINAR H., EVRANOS B., YORGUN H., ŞAHİNER M. L., KAYA E. B., ÖZER N., Tokgozoglu L., et al.
AMERICAN JOURNAL OF CARDIOLOGY, vol.115, no.5, pp.647-651, 2015 (SCI-Expanded)
- X. **Serum Galectin-3 Level Predicts the Extent of Left Atrial Fibrosis in Lone Atrial Fibrillation Patients**
Gurses K. M., Yalcin M. U., Kocyigit D., Canpinar H., Canpolat U., Evranos B., Yorgun H., Sahiner M. L., Kaya E. B., Guc D., et al.
CIRCULATION, vol.130, 2014 (SCI-Expanded)
- XI. **Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination**
UĞUR H. Ç., Taşpınar M., Ilgaz S., Sert F., CANPINAR H., Rey J. A., Castresana J. S., SUNGUROĞLU A.
MOLECULAR BIOLOGY REPORTS, vol.41, no.2, pp.697-703, 2014 (SCI-Expanded)
- XII. **Effects of gamma irradiation on cell cycle, apoptosis and telomerase activity in p53 wild-type and deficient HCT116 colon cancer cell lines.**
Halacli S., Canpinar H., Cimen E., Sunguroglu A.
Oncology letters, vol.6, pp.807-810, 2013 (SCI-Expanded)
- XIII. **Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells**
Taspınar M., Ilgaz S., Ozdemir M., Ozkan T., ÖZTUNA D., CANPINAR H., Rey J. A., SUNGUROĞLU A., Castresana J. S., UĞUR H. Ç.
TUMOR BIOLOGY, vol.34, no.3, pp.1935-1947, 2013 (SCI-Expanded)
- XIV. **Does N-Acetyl Cysteine Protect Against Apoptosis in HL60 Cell Line?**
AKSOY Y., Kesik K., CANPINAR H.
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.35, no.4, pp.333-339, 2010 (SCI-Expanded)
- XV. **Effects of autologous and homologous blood transfusion on TNF-alpha levels and survival in an**

intraabdominal infection model

KILIÇ Y. A., CANPINAR H., GÜÇ D., Sayek I.

ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY, vol.15, no.4, pp.324-329, 2009 (SCI-Expanded)

- XVI. **Soluble trail and BAFF levels in multiple sclerosis during interferon-beta therapy**
Kurue A., Aydin O. F., Guec D., Sayat G., Canpinar H., Yoeruebulut M., KARABUDAK R.
JOURNAL OF NEUROIMMUNOLOGY, vol.203, no.2, pp.137-138, 2008 (SCI-Expanded)
- XVII. **Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML**
Aksu S., Beyazit Y., Haznedaroglu I. C., Canpinar H., Kekilli M., ÜNER A., Sayinalp N., Bueyuekasik Y., Goker H., Ozcebe O. I.
LEUKEMIA & LYMPHOMA, vol.47, no.5, pp.891-896, 2006 (SCI-Expanded)
- XVIII. **Enhanced expression of the local haematopoietic bone marrow renin-angiotensin system in polycythemia Rubra vera**
Aksu S., Beyazit Y., Haznedaroglu I., Kekilli M., Canpinar H., Misirlioglu M., ÜNER A., Tuncer S., Sayinalp N., Buyukasik Y., et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.33, no.6, pp.661-667, 2005 (SCI-Expanded)
- XIX. **Water-soluble green perylene diimide (PDI) dyes as potential sensitizers for photodynamic therapy**
Yukruk F., Dogan A., Canpinar H., Guc D., Akkaya E.
ORGANIC LETTERS, vol.7, no.14, pp.2885-2887, 2005 (SCI-Expanded)
- XX. **Effects of prophylactic thyroid hormone replacement in euthyroid Hashimoto's thyroiditis**
Aksoy D., Kerimoglu U., Okur H., Canpinar H., Karaagaoglu E., Yetgin S., Kansu E., Gedik O.
ENDOCRINE JOURNAL, vol.52, no.3, pp.337-343, 2005 (SCI-Expanded)
- XXI. **Cerebrospinal fluid soluble CD27 levels in children with non-Hodgkin lymphomas**
Yalcin B., Canpinar H., Kutluk M., Varan A., Akyuz C., Buyukpamukcu M.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.21, no.8, pp.717-723, 2004 (SCI-Expanded)
- XXII. **A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia**
Koc Y., Oyan B., Kars A., Tekuzman G., Canpinar H., Kansu E.
HEMATOLOGICAL ONCOLOGY, vol.22, no.2, pp.43-53, 2004 (SCI-Expanded)
- XXIII. **Effect of fludarabine on leukocyte functions**
Dogan A., Dogan A., Canpinar H., Duzguncinar O., Demirpence E.
CHEMOTHERAPY, vol.50, no.6, pp.283-288, 2004 (SCI-Expanded)
- XXIV. **Myeloprotective effect of short term prechemotherapy recombinant granulocyte-macrophage colony stimulating factor**
Akyuz C., Caglar K., Varan A., Koseoglu V., Canpinar H., Kutluk T., Buyukpamukcu M.
MEDICAL AND PEDIATRIC ONCOLOGY, vol.38, no.1, pp.67-69, 2002 (SCI-Expanded)
- XXV. **Correlation of flow cytometric parameters and transferrin receptors with gallium-67 scintigraphic images in lymphoma patients**
Kiratli P., Canpinar H., Ruacan S., Kansu E.
NUCLEAR MEDICINE COMMUNICATIONS, vol.21, no.10, pp.925-931, 2000 (SCI-Expanded)
- XXVI. **The effect of angiotensin-converting enzyme inhibitors on adhesion molecules and cytokines in congestive heart failure**
Sade E., Canpinar H., Yildirim A., Oto A., Kansu E., Guc D., Tokgozoglul.
EUROPEAN HEART JOURNAL, vol.21, pp.661, 2000 (SCI-Expanded)
- XXVII. **Gastric lymphomas in Turkey - Analysis of prognostic factors with special emphasis on flow cytometric DNA content**
Aydin Z., Barista I., Canpinar H., Sungur A., Tekuzman G.
CANCER, vol.89, no.1, pp.12-20, 2000 (SCI-Expanded)
- XXVIII. **DNA content and proliferative activity in children with neuroblastoma**
Yalcin B., Kutluk T., Kansu E., Gogus S., Canpinar H., Akyuz C., Buyukpamukcu M.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.17, no.1, pp.45-54, 2000 (SCI-Expanded)

XXIX. **Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies**

Guc D., Canpinar H., Kucukaksu C., Kansu E.

EUROPEAN JOURNAL OF HAEMATOLOGY, vol.64, no.1, pp.3-9, 2000 (SCI-Expanded)

XXX. **P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy**

Kostakoglu L., Guc D., Canpinar H., Kars A., Alper E., Kiratli P., Hayran M., Gunduz U., Kansu E.

JOURNAL OF NUCLEAR MEDICINE, vol.39, no.7, pp.1191-1197, 1998 (SCI-Expanded)

XXXI. **Correlation of the findings of Tl-201 and tc-99m-sestamibi (MIBI) SPECT with proliferative index and DNA ploidy in patients with astrocytic tumors.**

Elahi N., Kostakoglu L., Canpinar H., Uzal D., Hayran M., Nabaie M., Bekdik C., Kansu E.

JOURNAL OF NUCLEAR MEDICINE, vol.38, no.5, pp.1008, 1997 (SCI-Expanded)

Articles Published in Other Journals

I. **Serum galectin-3 level predicts early recurrence following successful direct-current cardioversion in persistent atrial fibrillation patients.**

Gürses K., Yalçın M., Koçyiğit D., Canpinar H., Ateş A., Canpolat U., Yorgun H., Güç D., Aytemir K.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, vol.47, pp.564-571, 2019 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

I. **Role of the Radiosensitizing Effect of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Squamous Cell Cancer Cell Lines**

ESEN Ç. S. B., GEDİK M. E., GÜNAYDIN G., CANPINAR H., YEDEKÇİ F. Y., YILDIZ F., GÜLTEKİN M.

ASTRO Annual 2022 Meeting, United States Of America, 23 - 26 October 2022, vol.114

II. **Vitamin D replacement ameliorates serum lipoprotein functions, adipokine profile and subclinical atherosclerosis in premenopausal women**

KOÇYIĞIT D., GRECO D., ADORNI M. P., MARCHI C., RONDA N., BERNINI F., GÜRSES K. M., CANPINAR H., OĞUZ S. H., GÜÇ D., et al.

American Heart Association Scientific Sessions 2017, 11 - 15 November 2017, vol.136, pp.12124

III. **Gut microbiota play a role in calcific aortic valve stenosis**

KOÇYIĞIT D., GÜRSES K. M., STAHLMAN M., BOREN J., SOYAL M. F. T., CANPINAR H., GÜÇ D., AYHAN E. A., HAZIROLAN T., AYTEMİR K., et al.

American Heart Association Scientific Sessions 2017, 11 - 15 November 2017, vol.136, pp.12134

IV. **Dual effects of chlorophylline on breast cancer cell proliferation in vivo and in vitro**

ÖZCAN M., Musad Y., ESENDAĞLI G., CANPINAR H., AKSOY Y.

42nd Congress of the Federation-of-European-Biochemical-Societies (FEBS) on From Molecules to Cells and Back, Jerusalem, Israel, 10 - 14 September 2017, vol.284, pp.259

V. **Serum Galectin 3 Levels Are Associated With Epicardial Adipose Tissue Thickness in Atrial Fibrillation Patients**

Gürses K. M., YALÇIN M. U., KOÇYIĞIT D., EVRANOS B., ŞAHİNER M. L., KAYA E. B., CANPINAR H., GÜÇ D., ÖZER N., AYTEMİR K.

12. Uluslararası Kardiyoloji ve Kardiyovasküler Cerrahide Yenilikler Kongresi, 10 - 13 March 2016

VI. **Enhanced Peripheral Monocyte Toll Like Receptor Expression in Persistent Atrial Fibrillation Patients**

Gürses K. M., YALÇIN M. U., KOÇYIĞIT D., EVRANOS B., ŞAHİNER M. L., KAYA E. B., CANPINAR H., GÜÇ D., ÖZER N., AYTEMİR K.

12. Uluslararası Kardiyoloji ve Kardiyovasküler Cerrahide Yenilikler Kongresi, 10 - 13 March 2016

- VII. **OP 136 Relationship Between Serum Anti M2 muscarinic Receptor Levels and Atrial Electromechanical Delay in Patients Diagnosed with Paroxysmal Atrial Fibrillation**
Yalcin M. U., Gurses K. M., Kocyigit D., CANPOLAT U., Canpinar H., EVRANOS B., YORGUN H., ŞAHİNER M. L., KAYA E. B., Oto M. A., et al.
11th International Congress of Update in Cardiology and Cardiovascular Surgery — March 26-29, 2015, 26 - 29 March 2015
- VIII. **OP 135 Relationship Between Serum Galectin 3 Levels and Atrial Electromechanical Delay in Patients with Paroxysmal Atrial Fibrillation**
YALÇIN M. U., KADRİ MURAT G., KOÇYİĞİT D., CANPOLAT U., CANPINAR H., EVRANOS B., YORGUN H., ŞAHİNER M. L., KAYA E. B., OTO A., et al.
11th International Congress of Update in Cardiology and Cardiovascular Surgery — March 26-29, 2015, 26 - 29 March 2015, vol.26, pp.635-640
- IX. **Relationship Between Serum Anti M2 muscarinic Receptor Levels and Atrial Electromechanical Delay in Patients Diagnosed with Paroxysmal Atrial Fibrillation**
Yalçın M., Gürses K., KOÇYİĞİT D., CANPOLAT U., CANPINAR H., EVRANOS B., YORGUN H., ŞAHİNER M. L., KAYA E. B., Oto M., et al.
11th International Congress of Update in Cardiology and Cardiovascular Surgery — March 26-29, 2015, 26 - 29 March 2015
- X. **Relationship Between Serum Galectin 3 Levels and Atrial Electromechanical Delay in Patients with Paroxysmal Atrial Fibrillation**
Yalçın M., Gürses K., KOÇYİĞİT D., CANPOLAT U., CANPINAR H., EVRANOS B., YORGUN H., ŞAHİNER M. L., KAYA E. B., Oto M., et al.
11th International Congress of Update in Cardiology and Cardiovascular Surgery — March 26-29, 2015, 26 - 29 March 2015
- XI. **SERUM GALECTIN-3 LEVEL PREDICTS RECURRENCE FOLLOWING SUCCESSFUL ELECTRICAL CARDIOVERSION IN PERSISTENT ATRIAL FIBRILLATION PATIENTS**
Gurses K., Yalcin M., Kocyigit D., Canpinar H., Evranos B., Yorgun H., Sahiner L., Kaya E. B., Kabakci G., Tokgozoglu L., et al.
Scientific Session of the American-College-of-Cardiology (ACC), California, United States Of America, 14 - 16 March 2015, vol.65
- XII. **Synthesis and biological evaluation of tetrahydrocarbazole derivative compounds as human glutathione s transferase p1 1 inhibitors and docking studies**
özcan m., CEYHAN D., UZGÖREN BARAN A., sargöl d., CANPINAR H., BÜBER E., AKSOY Y.
XVIII Congress of the Portuguese Biochemical Society, Coimbra, Portugal, 17 - 20 December 2014
- XIII. **Abstract 15474: Serum Galectin-3 Level Predicts the Extent of Left Atrial Fibrosis in Lone Atrial Fibrillation Patients**
GÜRSES K. M., YALÇIN M. U., KOÇYİĞİT D., CANPINAR H., CANPOLAT U., EVRANOS B., YORGUN H., ŞAHİNER M. L., KAYA E. B., GÜÇ D., et al.
American Heart Association Congress 2014, Chicago, Illinois, United States Of America, 15 - 19 November 2014, vol.130, pp.15474
- XIV. **Hydrazone derivative compounds as a substrate for human glutathione transferase P1 1 kinetics docking and cell culture analysis**
CEYHAN D., Özcan m., SARIGÖL D., UZGÖREN BARAN A., CANPINAR H., BÜBER E., AKSOY Y.
2nd International BAU-Drug Design Symposium, İstanbul, Turkey, 17 - 19 April 2014
- XV. **TRAIL and BAFF serial serum levels during interferon beta therapy in MS patients**
Kurue A., CANPINAR H., Aydin O. F., Sayat G., Yoeruebulut M., Guec D., KARABUDAK R.
13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Montreal, Canada, 17 - 20 September 2008, vol.14
- XVI. **The role of glutathione depletion on apoptotic signal forming in HL-60 cell lines**
Aksoy Y., Kesik K., Canpinar H., Guc D.

30th Congress of the Federation-of-European-Biochemical-Societies (FEBS)/9th IUBMB Conference, Budapest, Hungary, 2 - 07 July 2005, vol.272, pp.26

XVII. Cell adhesion-mediated drug resistance phenotype in HL60 cell line.

Canpinar H., Guc D., Kansu E.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102

Supported Projects

ÜNDEĞER BUCURGAT Ü., AYDIN DİLSİZ S., CANPINAR H., ÇAL T., ÖKÇESİZ A., Project Supported by Higher Education Institutions, PİTAVASTATİNİN OLASI APOPTOTİK ANTIOKSİDAN VE GENOTOKSİK ETKİLERİNİN İNSAN SERVİKS KANSER HÜCRE HATTINDA HELA DEĞERLENDİRİLMESİ, 2019 - 2020

CANPINAR H., Ahmadzadeh B., Gök B., Project Supported by Higher Education Institutions, TLR Agonistleri ile Aktive Olan Akciğer Kanseri Hücre Kültür Süpernatantlarının Makrofaj Polarizasyonuna Etkisinin Araştırılması, 2017 - 2018

ÜNDEĞER BUCURGAT Ü., AYDIN S., CANPINAR H., SARIAYDIN T., Project Supported by Higher Education Institutions, METFORMİNİN SİTOTOKSİK APOPTOTİK VE GENOTOKSİK ETKİLERİNİN İN VİTRO DEĞERLENDİRİLMESİ, 2017 - 2018

CANPINAR H., GÜÇ D., KOÇYİĞİT D., ZİMETTİ F., ZANOTTİ I., Project Supported by Higher Education Institutions, Kalsifik Aort Kapak Darlığı Patogenezinde Barsak Mikrobiyotasının Rolünün Araştırılması, 2017 - 2017

CANPINAR H., TUBITAK Project, HIV Proteaz İnhibitörü Ritonavirin Yeni Nanosüspansiyon Formülasyonunun Geliştirilmesi ve in vitro in vivo Değerlendirilmesi, 2015 - 2017

KAYA E. B., KOÇYİĞİT D., GÜRSES K. M., EVRANOS B., ŞAHİNER M. L., GÜÇ D., CANPINAR H., Project Supported by Higher Education Institutions, STABİL KORONER ARTER HASTALIĞINDA KORONER KOLLATERAL GELİŞİMİ VE PROGNOZDA ANGIOGENİN VE OSTEOPONTİNİN ROLÜ, 2015 - 2017

CANPINAR H., Project Supported by Higher Education Institutions, Akciğer Kanseri Hücrelerinde Toll Like Reseptörlerin Ekspresyonu ve Apoptozise olan etkisinin araştırılması, 2013 - 2015

Metrics

Publication: 76

Citation (WoS): 800

Citation (Scopus): 866

H-Index (WoS): 15

H-Index (Scopus): 15

Non Academic Experience

Hacettepe Üniversitesi Onkoloji Enstitüsü

Hacettepe Üniversitesi Onkoloji Enstitüsü